Philip Hodges
CIK: 0001705562
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)3 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
ALT
Altimmune, Inc.
Director
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- May 1, 2026ALT
Altimmune, Inc.
Award(A)DirectStock Options (option to buy)
48.8K shares- - Sep 25, 2025ALT
Altimmune, Inc.
Award(A)DirectStock Options (option to buy)
48.8K shares- - Sep 26, 2024ALT
Altimmune, Inc.
Award(A)DirectStock Options (option to buy)
34.9K shares-
1-3 of 3 transactions
About Hodges Philip
Hodges Philip (SEC CIK 0001705562) files insider reports with the SEC as Director of Altimmune, Inc. (ALT).
Signal8 holds 3 ownership filings by Hodges Philip, all Form 4s, filed between Sep 30, 2024 and May 1, 2026. Those filings report 3 transactions, from Sep 26, 2024 to May 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Hodges Philip's filings is in GAITHERSBURG, MD.
Recent filings by Hodges Philip
Other insiders filing for Altimmune, Inc. (ALT)
- Arbet-Engels Christophe, Chief Medical Officer
- WEAVER GREGORY L, Chief Financial Officer
- MENZIUSO RICHARD THOMAS, Principal Accounting Officer
- Richardson Linda M, Chief Commercial Officer
- Durso Jerome Benedict, President and CEO
- Roberts M Scot, Chief Scientific Officer